

Press release

Contact:
Jeff Bork, President and CEO
Tel: +46 730 37 53 34, jeff.bork@eu.biotage.com

Biotage AB
Kungsgatan 76
SE-75318 Uppsala
Tel: 018 56 59 00
www.biotage.com

Uppsala February 22, 2006

Global option program for employees in Biotage

The board of directors has, in accordance with an authorisation from the annual shareholders' meeting held on April 27, 2005, adopted a global option program for employees within the Biotage group – Biotage AB Global Share Option Plan 2005.

The board of directors has further, in accordance with an authorisation from the above mentioned shareholders' meeting, resolved to allot 549 600 employee stock options under the option program, of which members of the group management receive a maximum of 45 000 stock options each, members of the junior management receive a maximum of 10 000 stock options each, other members of management and key employees receive a maximum of 2 000 stock options each and other employees receive a maximum of 400 stock options each. The CEO and President of the company has not been allotted any of the employee stock options.

Each stock option entitles the holder to acquire one ordinary share in Biotage at an exercise price of SEK 11.83. The stock options have an exercise period of 7 years and can be exercised after one year until three years following the date of allotment with one third of the number of allotted options for each one year period. The stock options require, in principal, that the holder is an employee of the group at the time of exercise.

In order to cover Biotage's commitments in relation to the employee stock options allotted under the program, the board of directors has also resolved to issue a maximum of 640 000 warrants to subscribe for new shares. The issue is based on the authorization from the annual shareholders' meeting held on April 27, 2005. The warrants entitle to subscription of a maximum of 640 000 ordinary shares in the company. Each warrant has an exercise period of 7 years and entitles the holder to subscribe to one ordinary share in Biotage at an exercise price of SEK 11.83. A bank appointed by the board or directors has right to subscribe for the warrants.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005

operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the world's top 30 pharmaceutical companies, the world's top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 330 employees and had sales of 430 MSEK in 2005. Biotage is listed on the Stockholm stock exchange. Website:

www.biotage.com